Hologic’s (HOLX) “Hold (C-)” Rating Reaffirmed at Weiss Ratings

Hologic (NASDAQ:HOLX)‘s stock had its “hold (c-)” rating reissued by research analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

Several other research firms also recently commented on HOLX. Morgan Stanley upped their price target on shares of Hologic from $65.00 to $69.00 and gave the company an “equal weight” rating in a research note on Thursday, July 31st. UBS Group boosted their price objective on shares of Hologic from $65.00 to $70.00 and gave the company a “neutral” rating in a report on Thursday, July 31st. Mizuho set a $75.00 price objective on Hologic in a research note on Thursday, July 31st. Argus increased their target price on Hologic from $80.00 to $90.00 and gave the stock a “buy” rating in a report on Friday, September 19th. Finally, Stephens reissued an “overweight” rating and set a $78.00 target price on shares of Hologic in a report on Thursday, September 18th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $80.15.

Hologic Trading Up 0.9%

Shares of NASDAQ:HOLX opened at $68.34 on Wednesday. Hologic has a 12-month low of $51.90 and a 12-month high of $84.39. The stock has a market cap of $15.20 billion, a PE ratio of 28.36, a P/E/G ratio of 2.32 and a beta of 0.63. The business has a 50 day moving average of $67.10 and a 200-day moving average of $63.22. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.03. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The firm’s revenue for the quarter was up 1.2% compared to the same quarter last year. During the same period last year, the firm posted $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, equities research analysts forecast that Hologic will post 4.28 earnings per share for the current year.

Insider Buying and Selling

In other Hologic news, CEO Stephen P. Macmillan sold 138,358 shares of the business’s stock in a transaction dated Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the completion of the transaction, the chief executive officer owned 1,234,624 shares of the company’s stock, valued at approximately $82,682,769.28. The trade was a 10.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.88% of the company’s stock.

Institutional Trading of Hologic

A number of hedge funds have recently added to or reduced their stakes in HOLX. Farther Finance Advisors LLC lifted its stake in shares of Hologic by 22.3% in the 1st quarter. Farther Finance Advisors LLC now owns 1,835 shares of the medical equipment provider’s stock valued at $113,000 after acquiring an additional 335 shares during the last quarter. Pallas Capital Advisors LLC increased its holdings in Hologic by 39.4% in the 1st quarter. Pallas Capital Advisors LLC now owns 4,356 shares of the medical equipment provider’s stock worth $269,000 after purchasing an additional 1,232 shares in the last quarter. Yousif Capital Management LLC increased its holdings in Hologic by 4.0% in the 1st quarter. Yousif Capital Management LLC now owns 48,066 shares of the medical equipment provider’s stock worth $2,969,000 after purchasing an additional 1,847 shares in the last quarter. SG Americas Securities LLC increased its holdings in Hologic by 116.6% in the 1st quarter. SG Americas Securities LLC now owns 9,609 shares of the medical equipment provider’s stock worth $594,000 after purchasing an additional 5,172 shares in the last quarter. Finally, Integrated Advisors Network LLC grew its holdings in shares of Hologic by 5.4% during the first quarter. Integrated Advisors Network LLC now owns 5,603 shares of the medical equipment provider’s stock worth $346,000 after purchasing an additional 289 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.